{{Rsnum
|rsid=12553173
|Gene=CA9
|Chromosome=9
|position=35674104
|Orientation=plus
|ReferenceAllele=T
|GMAF=0.2006
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(C;C)
|geno2=(C;T)
|geno3=(T;T)
|Gene_s=ARHGEF39,CA9
}}{{ population diversity
| geno1=(C;C)
| geno2=(C;T)
| geno3=(T;T)
| CEU | 1.8 | 27.4 | 70.8
| HCB | 3.6 | 31.4 | 65.0
| JPT | 3.5 | 13.3 | 83.2
| YRI | 20.5 | 41.1 | 38.4
| ASW | 14.0 | 43.9 | 42.1
| CHB | 3.6 | 31.4 | 65.0
| CHD | 2.8 | 31.2 | 66.1
| GIH | 0.0 | 9.9 | 90.1
| LWK | 21.8 | 50.9 | 27.3
| MEX | 0.0 | 15.5 | 84.5
| MKK | 5.8 | 44.2 | 50.0
| TSI | 1.0 | 23.5 | 75.5
| HapMapRevision=28
}}
[http://www.urotoday.com/38/browse_categories/renal_cancer/asco_2009__use_of_ca9_gene_single_nucleotide_polymorphisms_to_predict_prognosis_and_treatment_response_of_metastatic_renal_cell_carcinoma__session_highlights06032009.html news] Metastatic Renal Cell Carcinoma patients with rs12553173(C) had an improved median survival (27.3 vs. 13.6 months, p=0.0431) and a greater likelihood of response to IL-2 (57% vs. 22%, p=0.081)

{{PMID Auto
|PMID=19539328
|Title=CA9 gene: single nucleotide polymorphism predicts metastatic renal cell carcinoma prognosis.
}}

{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}